Full Transcript Rapamycin for Longevity Overview 0:00 If you're even slightly 0:00 If you're even slightly interested in the field of 0:01 interested in the field of 0:01 interested in the field of longevity, you've 0:02 longevity, you've 0:02 longevity, you've probably heard of 0:02 probably heard of 0:02 probably heard of rapamycin. And look 0:03 rapamycin. And look , I think the mTOR science behind 0:04 , I think the mTOR science behind 0:05 this 0:05 this is basically sound. 0:06 is basically sound. 0:06 is basically sound. What is not so 0:07 What is not so 0:07 What is not so reliable is the 0:07 reliable is the 0:07 reliable is the evidence in humans. And 0:08 evidence in humans. And 0:08 evidence in humans. And depending on the history of 0:09 depending on the history of 0:09 depending on the history of your immune 0:10 your immune 0:10 your immune system, this gap 0:10 system, this gap 0:11 system, this gap either doesn't bother me at all 0:11 either doesn't bother me at all 0:11 either doesn't bother me at all or becomes a 0:12 or becomes a 0:12 or becomes a complete hindrance. 0:13 complete hindrance. 0:13 complete hindrance. Today I will show you 0:14 Today I will show you why I hold this 0:14 why I hold this 0:14 why I hold this opinion and 0:15 opinion and 0:15 opinion and which of these two 0:16 which of these two 0:16 which of these two camps you may 0:16 camps you may 0:17 camps you may belong to. So, welcome 0:17 belong to. So, welcome 0:17 belong to. So, welcome back to my 0:18 back to my 0:18 back to my podcast. I am Dr. 0:19 podcast. I am Dr. 0:19 podcast. I am Dr. Greg Jones, a naturopath 0:20 Greg Jones, a naturopath 0:20 Greg Jones, a naturopath and founder of 0:21 and founder of 0:21 and founder of Innovate Wellness Center 0:22 Innovate Wellness Center 0:22 Innovate Wellness Center here in Phoenix, 0:22 here in Phoenix, 0:22 here in Phoenix, Arizona. Here's a quick 0:23 Arizona. Here's a quick 0:23 Arizona. Here's a quick warning. 0:24 warning. 0:24 warning. Rapamycin is a 0:25 Rapamycin is a 0:25 Rapamycin is a prescription drug 0:26 prescription drug . This video is for 0:27 . This video is for 0:27 . This video is for educational 0:27 educational 0:27 educational purposes only and is not 0:28 purposes only and is not 0:28 purposes only and is not medical advice, and 0:29 medical advice, and 0:29 medical advice, and nothing herein is 0:29 nothing herein is 0:29 nothing herein is a recommendation for 0:30 a recommendation for 0:30 a recommendation for you 0:31 you 0:31 you to personally begin taking it. But 0:32 to personally begin taking it. But 0:32 to personally begin taking it. But here's something that might 0:33 here's something that might 0:33 here's something that might make you stop for a moment 0:34 make you stop for a moment 0:34 make you stop for a moment . The same 0:35 . The same 0:35 . The same drug that a 0:36 drug that a 0:37 transplant patient 0:37 transplant patient takes to prevent the body from 0:38 takes to prevent the body from 0:38 takes to prevent the body from rejecting the new 0:38 rejecting the new 0:38 rejecting the new kidney is the same 0:39 kidney is the same 0:39 kidney is the same drug that 0:40 drug that 0:40 drug that biohackers 0:40 biohackers 0:40 biohackers use to 0:41 use to 0:41 use to try to live 0:42 try to live 0:42 try to live longer. This drug is 0:43 longer. This drug is rapamycin, also 0:43 rapamycin, also 0:43 rapamycin, also known by its 0:44 known by its 0:44 known by its pharmaceutical 0:45 pharmaceutical 0:45 pharmaceutical name sirolimus, and 0:46 name sirolimus, and 0:46 name sirolimus, and for the rest of the video 0:46 for the rest of the video 0:46 for the rest of the video I'll call it 0:47 I'll call it 0:47 I'll call it rapamycin because that's the 0:48 rapamycin because that's the 0:48 rapamycin because that's the name you'll 0:49 name you'll 0:49 name you'll see everywhere in the 0:49 see everywhere in the 0:49 see everywhere in the longevity field. 0:50 longevity field. 0:50 longevity field. It was originally 0:51 It was originally 0:51 It was originally developed as an 0:51 developed as an 0:51 developed as an immunosuppressant,
The mTOR Mechanism Explained 0:52 immunosuppressant, 0:52 immunosuppressant, specifically to 0:53 specifically to 0:53 specifically to protect a 0:53 protect a 0:53 protect a transplanted 0:54 transplanted 0:54 transplanted organ from attack by the 0:55 organ from attack by the 0:56 body's own immune system. 0:56 body's own immune system. So how did an anti- 0:57 So how did an anti- 0:57 So how did an anti- 0:58 transplant rejection drug become 0:59 transplant rejection drug become one of the most 0:59 one of the most 0:59 one of the most talked-about longevity compounds 1:00 talked-about longevity compounds 1:02 we know of? 1:02 we know of? The answer lies in 1:02 The answer lies in 1:02 The answer lies in a switch inside 1:03 a switch inside 1:03 a switch inside your body, 1:04 your body, 1:04 your body, inside your 1:05 inside your 1:05 inside your cells, 1:05 cells, 1:05 cells, called mTOR, which acts 1:06 called mTOR, which acts 1:06 called mTOR, which acts as a master 1:06 as a master 1:06 as a master growth controller. When 1:07 growth controller. When 1:08 growth controller. When mTOR is activated, your 1:09 mTOR is activated, your 1:09 mTOR is activated, your cells are told to 1:09 cells are told to 1:09 cells are told to grow and 1:10 grow and 1:10 grow and divide. When mTOR 1:11 divide. When mTOR 1:11 divide. When mTOR is blocked, your 1:12 is blocked, your 1:12 is blocked, your cells go into 1:13 cells go into 1:13 cells go into another mode, a mode of 1:14 another mode, a mode of 1:14 another mode, a mode of cleansing and 1:14 cleansing and 1:14 cleansing and repair, a process 1:15 repair, a process 1:15 repair, a process called 1:16 called 1:16 called autophagy. And 1:17 autophagy. And 1:17 autophagy. And rapamycin blocks mTOR, 1:18 rapamycin blocks mTOR, 1:18 rapamycin blocks mTOR, which is why 1:19 which is why 1:19 which is why scientists are interested in 1:20 scientists are interested in 1:20 scientists are interested in it beyond just as a 1:21 it beyond just as a 1:21 it beyond just as a transplant drug. 1:22 transplant drug. 1:22 transplant drug. So imagine mTOR as a 1:23 So imagine mTOR as a 1:23 So imagine mTOR as a factory foreman 1:24 factory foreman 1:24 factory foreman who never 1:25 who never 1:25 who never calls a repair 1:26 calls a repair 1:26 calls a repair shift, always 1:26 shift, always 1:26 shift, always pushing the line 1:27 pushing the line 1:27 pushing the line to produce more 1:28 to produce more 1:28 to produce more and more, never 1:29 and more, never 1:29 and more, never stopping for 1:29 stopping for 1:29 stopping for repairs. When you 1:30 repairs. When you 1:30 repairs. When you block 1:31 block 1:31 block this technician's signal, they 1:32 this technician's signal, they 1:32 this technician's signal, they finally call a 1:33 finally call a 1:33 finally call a repair crew. And
Animal Lifespan Studies Reviewed 1:34 repair crew. And 1:34 repair crew. And this is a theory. So how does the data 1:35 this is a theory. So how does the data 1:35 this is a theory. So how does the data actually 1:36 actually 1:36 actually support this? And 1:37 support this? And 1:37 support this? And here's the moment when the data 1:38 here's the moment when the data 1:38 here's the moment when the data really convinced 1:39 really convinced 1:39 really convinced me that the theory had a 1:39 me that the theory had a 1:40 me that the theory had a strong 1:40 strong 1:40 strong basis, not just a 1:41 basis, not just a 1:41 basis, not just a plausible 1:42 plausible 1:42 plausible mechanism. In a 1:42 mechanism. In a 1:42 mechanism. In a 2009 study, 1:43 2009 study, 1:43 2009 study, mice given 1:44 mice given 1:44 mice given rapamycin starting at the 1:46 rapamycin starting at the 1:47 equivalent of 60 1:47 equivalent of 60 years of age lived longer: 1:48 years of age lived longer: 1:48 years of age lived longer: 14% longer than females and 9% 1:49 14% longer than females and 9% longer than males. And this was 1:50 longer than males. And this was 1:50 longer than males. And this was measured at a time 1:51 measured at a time 1:51 measured at a time when 90% of the group had already 1:52 when 90% of the group had already 1:52 when 90% of the group had already died. Цей ефект 1:53 died. Цей ефект 1:53 died. Цей ефект спостерігався у 1:54 спостерігався у 1:54 спостерігався у трьох незалежних 1:55 трьох незалежних 1:55 трьох незалежних дослідницьких 1:55 дослідницьких 1:55 дослідницьких центрах, а не в одній 1:56 центрах, а не в одній 1:56 центрах, а не в одній лабораторії, з 1:56 лабораторії, з 1:56 лабораторії, з використанням 1:57 використанням 1:57 використанням генетично 1:57 генетично 1:57 генетично перевірених мишей, 1:58 перевірених мишей, 1:58 перевірених мишей, підібраних 1:58 підібраних 1:58 підібраних спеціально для того, 1:59 спеціально для того, 1:59 спеціально для того, щоб виключити 1:59 щоб виключити 1:59 щоб виключити випадкові результати 2:00 випадкові результати , пов'язані з одним 2:01 , пов'язані з одним 2:01 , пов'язані з одним генетичним фоном. In a 2:02 генетичним фоном. In a 2:02 генетичним фоном. In a follow-up 2:02 follow-up 2:02 follow-up 2:04 dose- response study in 2014, 2:05 response study in 2014, 2:05 response study in 2014, the results were further 2:06 the results were further 2:06 the results were further confirmed: at the 2:07 confirmed: at the 2:07 confirmed: at the highest dose, 2:07 highest dose, 2:07 highest dose, median 2:08 median 2:08 median lifespan increased by 23% in 2:09 lifespan increased by 23% in 2:09 lifespan increased by 23% in males and 26% in females 2:10 males and 26% in females . And this is not just one 2:11 . And this is not just one 2:11 . And this is not just one successful study 2:12 successful study 2:12 successful study gathering dust in a 2:13 gathering dust in a 2:13 gathering dust in a drawer in one 2:14 drawer in one 2:14 drawer in one laboratory. It 2:14 laboratory. It 2:14 laboratory. It was reproduced at 2:15 was reproduced at 2:15 was reproduced at different sites and was 2:16 different sites and was 2:16 different sites and was predictably 2:16 predictably 2:18 dose-dependent. And now 2:18 dose-dependent. And now here's the part that 2:18 here's the part that 2:18 here's the part that really caught 2:19 really caught 2:19 really caught my attention. And sometimes the 2:20 my attention. And sometimes the 2:20 my attention. And sometimes the constant use of 2:21 constant use of 2:21 constant use of rapamycin 2:22 rapamycin 2:22 rapamycin skips this point altogether. 2:23 skips this point altogether. 2:23 skips this point altogether. In a separate 2:23 In a separate 2:23 In a separate 2016 study, 2:24 2016 study, 2:24 2016 study, scientists tested 2:25 scientists tested 2:25 scientists tested two different doses: a higher one 2:26 two different doses: a higher one 2:26 two different doses: a higher one administered 2:27 administered 2:27 administered by injection and a lower one 2:28 by injection and a lower one 2:28 by injection and a lower one added to the 2:29 added to the 2:29 added to the diet. At the higher 2:30 diet. At the higher 2:30 diet. At the higher dose, male mice 2:31 dose, male mice 2:31 dose, male mice received an even greater 2:32 received an even greater 2:32 received an even greater advantage in 2:32 advantage in 2:32 advantage in lifespan, but 2:33 lifespan, but 2:33 lifespan, but females received no 2:34 females received no 2:34 females received no benefit. And, 2:35 benefit. And, 2:35 benefit. And, worse still, these females 2:36 worse still, these females who received the higher 2:37 who received the higher 2:37 who received the higher dose developed aggressive blood cancer 2:38 dose developed aggressive blood cancer 2:40 more often than those who 2:40 more often than those who were not treated. And at the
The Sex Specific Dosing Problem 2:41 were not treated. And at the 2:41 were not treated. And at the lower dietary 2:41 lower dietary 2:41 lower dietary dose, both males and females 2:42 dose, both males and females 2:42 dose, both males and females lived longer, 2:43 lived longer, 2:43 lived longer, without comparable 2:44 without comparable 2:44 without comparable spikes in that 2:45 spikes in that 2:45 spikes in that aggressive cancer. 2:45 aggressive cancer. 2:46 aggressive cancer. Let's just 2:46 Let's just 2:46 Let's just think about this for a moment. 2:47 think about this for a moment. 2:47 think about this for a moment. More of 2:48 More of 2:48 More of the drug didn't just 2:49 the drug didn't just 2:49 the drug didn't just stop helping 2:50 stop helping 2:50 stop helping one sex, it 2:51 one sex, it 2:51 one sex, it actively harmed it. 2:52 actively harmed it. 2:52 actively harmed it. And this single 2:52 And this single 2:52 And this single study showed 2:53 study showed 2:53 study showed me that it's not 2:54 me that it's not 2:54 me that it's not just about increasing the 2:55 just about increasing the 2:55 just about increasing the dose of the compound. Anyone who 2:56 dose of the compound. Anyone who 2:56 dose of the compound. Anyone who views this 2:57 views this 2:57 views this differently is essentially 2:58 differently is essentially 2:58 differently is essentially ignoring the real data. 2:59 ignoring the real data. 2:59 ignoring the real data. So, after 2:59 So, after 2:59 So, after reading these 3:00 reading these 3:01 animal studies, my 3:01 animal studies, my skepticism about the 3:02 skepticism about the 3:02 skepticism about the biological basis has 3:03 biological basis has 3:03 biological basis has almost disappeared. As 3:04 almost disappeared. As 3:04 almost disappeared. As for mice, the 3:05 for mice, the 3:05 for mice, the issue 3:06 issue 3:06 issue is closed for me. I understand. 3:07 is closed for me. I understand. 3:07 is closed for me. I understand. Choosing dietary 3:08 Choosing dietary 3:08 Choosing dietary supplements can be 3:09 supplements can be 3:09 supplements can be confusing. 3:10 confusing. 3:10 confusing. There are hundreds of 3:10 There are hundreds of 3:10 There are hundreds of brands, conflicting 3:12 brands, conflicting 3:12 brands, conflicting claims, and no 3:12 claims, and no 3:12 claims, and no way to know what 3:13 way to know what 3:13 way to know what is actually beneficial 3:14 is actually beneficial 3:14 is actually beneficial and what will really affect 3:15 and what will really affect 3:15 and what will really affect your health. That's why 3:16 your health. That's why 3:16 your health. That's why I created 3:17 I created 3:19 Dr. Jones' Supplement Store. Every 3:19 Dr. Jones' Supplement Store. Every product in the store 3:20 product in the store 3:20 product in the store for energy, 3:21 for energy, 3:21 for energy, gut health, sleep, 3:22 gut health, sleep, 3:22 gut health, sleep, hormone optimization 3:23 hormone optimization , recovery, and more is 3:24 , recovery, and more is 3:24 , recovery, and more is personally reviewed 3:25 personally reviewed , tested, and 3:25 , tested, and 3:25 , tested, and recommended. These are the 3:26 recommended. These are the 3:26 recommended. These are the formulas that I 3:27 formulas that I 3:27 formulas that I use myself and 3:28 use myself and 3:28 use myself and recommend to my 3:29 recommend to my 3:29 recommend to my patients, friends, and 3:30 patients, friends, and 3:30 patients, friends, and family. So, 3:30 family. So, 3:30 family. So, go to 3:31 go to 3:31 go to drjonesupplements.com, 3:31 drjonesupplements.com, 3:31 drjonesupplements.com, sign up for the 3:32 sign up for the 3:32 sign up for the email newsletter, 3:33 email newsletter, 3:33 email newsletter, and you will receive a 3:34 and you will receive a 3:34 and you will receive a 10% discount on your first order 3:35 10% discount on your first order . You will also receive 3:36 . You will also receive 3:36 . You will also receive exclusive 3:36 exclusive 3:36 exclusive protocols and insights 3:37 protocols and insights 3:37 protocols and insights that I share only 3:38 that I share only 3:38 that I share only with my community. 3:39 with my community. 3:39 with my community. So let's cut through the 3:40 So let's cut through the 3:40 So let's cut through the noise and choose 3:41 noise and choose 3:41 noise and choose what really works.
Human Clinical Trial Data Gap 3:42 what really works. 3:42 what really works. That's why the next 3:43 That's why the next 3:43 That's why the next part of my 3:43 part of my 3:43 part of my story 3:44 story 3:44 story upsets some people. Because 3:45 upsets some people. Because 3:45 upsets some people. Because as close as 3:46 as close as 3:46 as close as I think the results of the 3:46 I think the results of the 3:46 I think the results of the mouse study are, 3:47 mouse study are, 3:47 mouse study are, the situation with humans is 3:48 the situation with humans is 3:48 the situation with humans is not even close 3:48 not even close 3:49 not even close . And this is where 3:49 . And this is where 3:49 . And this is where my confidence 3:50 my confidence 3:50 my confidence drops, and I want to be 3:51 drops, and I want to be 3:51 drops, and I want to be honest about it, 3:52 honest about it, 3:52 honest about it, instead of keeping 3:53 instead of keeping 3:53 instead of keeping quiet. There is 3:54 quiet. There is 3:54 quiet. There is only one real 3:54 only one real 3:54 only one real randomized 3:55 randomized 3:55 randomized trial 3:56 trial 3:56 trial involving healthy 3:56 involving healthy 3:56 involving healthy adults who do not 3:57 adults who do not 3:57 adults who do not need 3:57 need 3:57 need a transplant, 3:58 a transplant, 3:58 a transplant, called Pearl. It was 3:59 called Pearl. It was 3:59 called Pearl. It was published in 4:00 published in 4:00 published in 2025, and 114 people aged 4:01 2025, and 114 people aged 4:01 2025, and 114 people aged 50 to 85 4:02 50 to 85 4:02 50 to 85 were followed 4:02 were followed 4:02 were followed for 48 weeks, 4:03 for 48 weeks, 4:03 for 48 weeks, comparing placebo with 4:04 comparing placebo with 4:04 comparing placebo with low weekly 4:06 low weekly 4:06 low weekly doses of rapamycin. 4:06 doses of rapamycin. 4:07 doses of rapamycin. The results show 4:08 The results show that safety was similar across 4:09 that safety was similar across 4:09 that safety was similar across groups, with women 4:09 groups, with women 4:10 groups, with women on the higher dose 4:10 on the higher dose 4:10 on the higher dose seeing improvements in 4:11 seeing improvements in 4:11 seeing improvements in muscle mass, 4:12 muscle mass, 4:12 muscle mass, reduced pain, and 4:13 reduced pain, and 4:13 reduced pain, and no change in visceral fat 4:14 no change in visceral fat 4:14 no change in visceral fat . But here's the 4:15 . But here's the 4:15 . But here's the part I want to 4:16 part I want to 4:16 part I want to delve into. This is where I 4:17 delve into. This is where I 4:17 delve into. This is where I mention biomarkers, and 4:18 mention biomarkers, and 4:18 mention biomarkers, and it did not assess 4:19 it did not assess 4:19 it did not assess mortality or 4:19 mortality or 4:19 mortality or life expectancy as an 4:20 life expectancy as an 4:20 life expectancy as an endpoint. And there 4:21 endpoint. And there 4:21 endpoint. And there is currently no 4:22 is currently no 4:22 is currently no trial of 4:23 trial of 4:23 trial of rapamycin on 4:23 rapamycin on 4:23 rapamycin on lifespan in 4:24 lifespan in 4:24 lifespan in humans. Now, to put it 4:25 humans. Now, to put it 4:25 humans. Now, to put it simply, translating 4:26 simply, translating 4:26 simply, translating these 4:27 these 4:27 these animal results into real 4:28 animal results into real 4:28 animal results into real benefits for humans 4:28 benefits for humans 4:28 benefits for humans remains quite 4:29 remains quite 4:29 remains quite unclear. So 4:30 unclear. So 4:30 unclear. So when I say there is 4:31 when I say there is 4:33 no evidence for people, that's exactly what I mean 4:33 no evidence for people, that's exactly what I mean . One short 4:34 . One short 4:34 . One short trial of 4:34 trial of 4:34 trial of biomarkers in a 4:35 biomarkers in a 4:35 biomarkers in a small group is 4:36 small group is 4:36 small group is not the same as proof that 4:36 not the same as proof that 4:36 not the same as proof that it extends a 4:37 it extends a 4:37 it extends a person's life. And this is a 4:38 person's life. And this is a 4:38 person's life. And this is a real gap. I'm 4:39 real gap. I'm 4:39 real gap. I'm not ignoring her. This is the whole
Who Should and Should Not Consider It 4:41 not ignoring her. This is the whole 4:41 not ignoring her. This is the whole reason why my 4:42 reason why my 4:42 reason why my verdict has two different 4:43 verdict has two different 4:43 verdict has two different answers depending 4:43 answers depending 4:43 answers depending on who asks. 4:44 on who asks. 4:44 on who asks. So, here's the breakdown 4:45 So, here's the breakdown 4:45 So, here's the breakdown on security and why 4:46 on security and why 4:46 on security and why the answer depends 4:47 the answer depends 4:47 the answer depends on who's asking 4:48 on who's asking 4:48 on who's asking me the question. And that's the 4:49 me the question. And that's the 4:49 me the question. And that's the real basis of how 4:50 real basis of how 4:50 real basis of how I think about 4:51 I think about 4:51 I think about rapamycin. So 4:52 rapamycin. So 4:52 rapamycin. So let me 4:52 let me 4:52 let me address 4:53 address 4:54 two different audiences directly, 4:54 two different audiences directly, because you are probably one 4:55 because you are probably one 4:55 because you are probably one of them. If your 4:56 of them. If your 4:56 of them. If your immune system is 4:57 immune system is 4:57 immune system is healthy, there is no 4:57 healthy, there is no 4:57 healthy, there is no diagnosis of 4:57 diagnosis of 4:57 diagnosis of autoimmune 4:58 autoimmune 4:58 autoimmune disease, you are not 4:59 disease, you are not 4:59 disease, you are not taking 4:59 taking 4:59 taking immunosuppressants, and you do not 5:00 immunosuppressants, and you do not 5:00 immunosuppressants, and you do not have a history of 5:00 have a history of 5:00 have a history of serious 5:01 serious 5:01 serious recurring infections, here is 5:02 recurring infections, here is 5:02 recurring infections, here is my position. I have no 5:03 my position. I have no 5:03 my position. I have no problem 5:03 problem 5:03 problem using 5:04 using 5:04 using rapamycin. It 5:05 rapamycin. It 5:05 rapamycin. It passes the 5:06 passes the 5:06 passes the safety threshold in the limited 5:06 safety threshold in the limited 5:06 safety threshold in the limited 5:08 human clinical trials that exist, and 5:10 animal safety data, at the correct 5:10 animal safety data, at the correct dose, are encouraging. And I'm 5:11 dose, are encouraging. And I'm 5:11 dose, are encouraging. And I'm not telling you to go out and 5:12 not telling you to go out and 5:12 not telling you to go out and start 5:13 start 5:13 start taking it. I'm saying that 5:14 taking it. I'm saying that 5:14 taking it. I'm saying that if you and your doctor 5:14 if you and your doctor 5:14 if you and your doctor decide to 5:15 decide to 5:15 decide to explore this, the arguments 5:16 explore this, the arguments 5:16 explore this, the arguments about safety for a 5:16 about safety for a 5:16 about safety for a healthy immune 5:17 healthy immune 5:17 healthy immune system don't 5:18 system don't 5:18 system don't scare me. Now, if 5:19 scare me. Now, if 5:19 scare me. Now, if you have an autoimmune 5:20 you have an autoimmune 5:20 you have an autoimmune disease, a 5:21 disease, a 5:21 disease, a history of 5:21 history of 5:22 history of immune system dysfunction, or 5:22 immune system dysfunction, or 5:23 immune system dysfunction, or frequently recurring 5:23 frequently recurring 5:23 frequently recurring serious illnesses, here is 5:24 serious illnesses, here is 5:25 serious illnesses, here is my position. I wo 5:25 my position. I wo 5:25 my position. I wo n't 5:26 n't 5:26 n't go near that. 5:27 go near that. 5:27 go near that. Rapamycin's original purpose 5:28 Rapamycin's original purpose 5:28 Rapamycin's original purpose was to suppress the 5:29 was to suppress the 5:29 was to suppress the immune system 5:29 immune system 5:29 immune system enough to 5:30 enough to 5:30 enough to stop 5:30 stop 5:30 stop organ rejection 5:31 organ rejection , even at the low, 5:32 , even at the low, 5:32 , even at the low, intermittent doses 5:33 intermittent doses 5:33 intermittent doses used for 5:34 used for 5:34 used for longevity. So you're 5:35 longevity. So you're 5:35 longevity. So you're still 5:35 still 5:35 still pushing an immune 5:36 pushing an immune 5:36 pushing an immune system that may 5:37 system that may 5:37 system that may already be fighting back in the 5:38 already be fighting back in the 5:38 already be fighting back in the wrong 5:38 wrong 5:38 wrong direction. And this is my 5:39 direction. And this is my 5:39 direction. And this is my division. These are two different 5:40 division. These are two different 5:40 division. These are two different answers for two 5:41 answers for two 5:41 answers for two different categories of 5:42 different categories of 5:42 different categories of people, and they are 5:42 people, and they are 5:42 people, and they are based on the same 5:43 based on the same 5:43 based on the same evidence. 5:44 evidence. 5:44 evidence. Now another
Compounded vs Pharmaceutical Grade 5:45 Now another 5:45 Now another practical thing. If 5:46 practical thing. If 5:46 practical thing. If you are in the healthy camp 5:47 you are in the healthy camp 5:47 you are in the healthy camp and are really going to 5:48 and are really going to 5:48 and are really going to discuss this with your 5:48 discuss this with your 5:48 discuss this with your doctor. Understand 5:49 doctor. Understand 5:49 doctor. Understand that most people 5:50 that most people 5:50 that most people who take 5:51 who take 5:51 who take rapamycin off- 5:51 rapamycin off- 5:51 rapamycin off- label for 5:52 label for 5:52 label for longevity are not 5:52 longevity are not 5:52 longevity are not getting the 5:53 getting the 5:53 getting the pharmaceutical version 5:54 pharmaceutical version . You get a 5:54 . You get a 5:54 . You get a custom-made 5:55 custom-made 5:55 custom-made version from a 5:56 version from a 5:56 version from a specialty 5:57 specialty 5:57 specialty pharmacy. A 5:58 pharmacy. A 5:58 pharmacy. A 2025 study found that 5:59 2025 study found that 5:59 2025 study found that custom-made 5:59 custom-made 5:59 custom-made rapamycin 6:00 rapamycin 6:00 rapamycin has significantly lower 6:01 has significantly lower 6:01 has significantly lower bioavailability than the 6:02 bioavailability than the 6:02 bioavailability than the commercial 6:03 commercial 6:03 commercial pharmaceutical 6:03 pharmaceutical 6:03 pharmaceutical drug: 6:04 drug: 6:04 drug: 6:05 approximately 31% is absorbed per 6:05 approximately 31% is absorbed per milligram. This means 6:06 milligram. This means 6:06 milligram. This means that the dose on the label 6:07 that the dose on the label 6:07 that the dose on the label and the dose 6:07 and the dose 6:09 your body actually receives can be 6:09 your body actually receives can be significantly different 6:09 significantly different . So, let's go back to where 6:11 . So, let's go back to where 6:11 . So, let's go back to where we started 6:12 we started . If you've heard 6:13 . If you've heard 6:13 . If you've heard rapamycin being touted as a 6:14 rapamycin being touted as a 6:14 rapamycin being touted as a proven "anti- 6:14 proven "anti- 6:16 aging pill" and wondered if the 6:17 if the 6:17 if the hype was justified, here's my 6:18 hype was justified, here's my 6:18 hype was justified, here's my answer. From a 6:19 answer. From a 6:19 answer. From a biological 6:20 biological 6:20 biological perspective, this may be 6:20 perspective, this may be 6:20 perspective, this may be one of the most 6:21 one of the most 6:21 one of the most sound 6:22 sound 6:22 sound approaches in 6:23 approaches in 6:23 approaches in longevity medicine. Whether 6:23 longevity medicine. Whether 6:23 longevity medicine. Whether this is enough for 6:24 this is enough for 6:24 this is enough for you depends 6:25 you depends 6:25 you depends solely on your 6:26 solely on your 6:26 solely on your immune system. So 6:27 immune system. So 6:27 immune system. So if this breakdown was 6:27 if this breakdown was 6:27 if this breakdown was helpful, please like 6:28 helpful, please like , subscribe for 6:29 , subscribe for 6:29 , subscribe for more 6:30 more 6:30 more research on 6:30 research on 6:31 research on hormones, peptides, and 6:31 hormones, peptides, and 6:31 hormones, peptides, and longevity medicine, 6:32 longevity medicine, 6:32 longevity medicine, and share this 6:33 and share this 6:33 and share this video with anyone who 6:34 video with anyone who 6:34 video with anyone who might need it. 6:35 might need it. 6:35 might need it. Thank you for watching. 6:36 Thank you for watching. 6:36 Thank you for watching. Dr. Greg Jones was with you 6:37 Dr. Greg Jones was with you 6:37 Dr. Greg Jones was with you , see you in the 6:38 , see you in the 6:38 , see you in the next video.
Comments